Genomic landscape and molecular risk in patients with DIPSS Low- and Intermediate-1 risk primary myelofibrosis (PMF)

被引：0
|
作者：
Panina, E. [1 ]
Stegelmann, F. [1 ]
Pahl, H. L. [2 ]
Koschmieder, S. [3 ]
Bommer, M. [4 ]
Schafhausen, P. [5 ]
Platzbecker, U. [6 ]
Griesshammer, M. [7 ]
Bruemmendorf, T. H. [3 ]
Doehner, H. [1 ]
Bullinger, L. [8 ]
Doehner, K. [1 ]
机构：
[1] Univ Hosp Ulm, Internal Med 3, Ulm, Germany
[2] Univ Med Ctr Freiburg, Div Mol Hematol, Fac Med, Freiburg, Germany
[3] Rhein Westfal TH Aachen, Fac Med, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Aachen, Germany
[4] Alb Fils Kliniken, Dept Internal Med Hematol Oncol Palliat Care & In, Goppingen, Germany
[5] Univ Med Ctr Hamburg Eppendorf, Dept Haematol & Oncol, Hubertus Wald Tumorzentrum, Hamburg, Germany
[6] Leipzig Univ Hosp, Med Clin & Policlin, Hematol & Cellular Therapy, Leipzig, Germany
[7] Univ Hosp Minden, Dept Hematol & Oncol, Minden, Germany
[8] Charite, Dept Hematol Oncol & Tumor Immunol, Campus Virchow Klinikum, Berlin, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V816
引用
收藏
页码：226 / 226
页数：1
相关论文
共 50 条
  • [1] RECOMBINANT INTERFERON- TREATMENT AFFECTS PROGNOSIS OF LOW-/INTERMEDIATE-1 DIPSS RISK IN EARLY/PREFIBROTIC PRIMARY MYELOFIBROSIS PATIENTS: A MONOCENTRIC STUDY
    Gambella, M.
    Bergamaschi, M.
    Carminati, E.
    Colombo, N.
    Miglino, M.
    Cea, M.
    Gobbi, M.
    Cagnetta, A.
    Lemoli, R. M.
    [J]. HAEMATOLOGICA, 2017, 102 : 101 - 101
  • [2] Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis
    Gill, Harinder
    Au, Lester
    Yim, Rita
    Chin, Lynn
    Li, Vivian
    Lee, Paul
    Leung, Garret Mk
    Lee, Carmen
    Wu, Tony Kwun Yat
    Ngai, Cheong
    Ho, Ryan
    Sin, Albert Chun Fung
    Hou, Hsin-An
    Chen, Chih-Cheng
    Kwong, Yok-Lam
    [J]. BLOOD, 2022, 140 : 1522 - 1522
  • [3] Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis: Durable Responses and Evidence of Disease Modification
    Gill, Harinder
    Au, Lester
    Leung, Garret Man Kit
    Tsai, Dorothy
    Yim, Rita
    Chin, Lynn
    Li, Vivian
    Lee, Paul
    Sin, Albert Chun Fung
    Hou, Hsin An
    Chen, Chih-Cheng
    Kwong, Yok Lam
    [J]. BLOOD, 2023, 142
  • [4] Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression
    Maffioli, Margherita
    Cervantes, Francisco
    Cazzola, Mario
    Vannucchi, Alessandro M.
    Morra, Enrica
    Caramazza, Domenica
    Mora, Barbara
    Giorgino, Toni
    Passamonti, Francesco
    [J]. BLOOD, 2014, 124 (21)
  • [5] Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score
    Gowin, Krisstina L.
    Ballen, Karen K.
    Ahn, Kwang Woo
    Hu, Zhen-Huan
    Liu, Ying
    Masarova, Lucia
    Verstovsek, Srdan
    Coakley, Maria
    Jain, Tania
    Kuykendall, Andrew
    Komrokji, Rami
    Wadleigh, Martha
    Patches, Sarah
    Arcasoy, Murat
    Green, Michael
    Kandarpa, Malathi
    Talpaz, Moshe
    Ali, Haris
    Gupta, Vikas
    Devlin, Rebecca
    Michaelis, Laura C.
    Hobbs, Gabriela S.
    Stein, Brady Lee
    Pariser, Ashley
    Gerds, Aaron T.
    Kuber, Kierstin
    Rampal, Raajit
    Alyea, Edwin P., III
    Popat, Uday
    Sobecks, Ronald
    Scott, Bart L.
    Mesa, Ruben
    Saber, Wael
    [J]. BLOOD, 2018, 132
  • [6] Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib
    Zarzour, Ahmad
    Tabarroki, Ali
    Visconte, Valeria
    Taftaf, Rokana
    Rogers, Heesun J.
    Ai, Jing
    Papadantonakis, Nikolaos
    Lichtin, Alan E.
    Saunthararajah, Yogen
    Stein, Brady L.
    Tiu, Ramon V.
    [J]. BLOOD, 2014, 124 (21)
  • [7] HIGH MOLECULAR RISK MUTATIONS ARE ASSOCIATED WITH CLINICAL RESPONSE AND OUTCOME IN INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
    Palandri, F.
    Bartoletti, D.
    Bonifacio, M.
    Iurlo, A.
    Benevolo, G.
    Elli, E. M.
    Auteri, G.
    Beggiato, E.
    Tieghi, A.
    Crugnola, M.
    Bosi, C.
    Ottaviani, E.
    Caocci, G.
    Polverelli, N.
    Cavazzini, F.
    Tiribelli, M.
    Pugliese, N.
    Binotto, G.
    Isidori, A.
    Lemoli, R. M.
    Cilloni, D.
    Martino, B.
    Abruzzese, E.
    Bocchia, M.
    Latagliata, R.
    Cavo, M.
    Vianelli, N.
    Breccia, M.
    Palumbo, G. A.
    [J]. HAEMATOLOGICA, 2021, 106 (10) : 84 - 85
  • [8] Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
    Harrison, Claire N.
    Talpaz, Moshe
    Mead, Adam J.
    [J]. LEUKEMIA & LYMPHOMA, 2016, 57 (10) : 2259 - 2267
  • [9] A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Harada, Hironori
    Shibayama, Hirohiko
    Jang, Jun Ho
    Shimazaki, Ryutaro
    Mitani, Kinuko
    Sawada, Kenichi
    Kim, Hyeoung-Joon
    [J]. BLOOD, 2014, 124 (21)
  • [10] Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
    Palandri, Francesca
    Tiribelli, Mario
    Benevolo, Giulia
    Tieghi, Alessia
    Cavazzini, Francesco
    Breccia, Massimo
    Bergamaschi, Micaela
    Sgherza, Nicola
    Polverelli, Nicola
    Crugnola, Monica
    Isidori, Alessandro
    Binotto, Gianni
    Heidel, Florian H.
    Buccisano, Francesco
    Martino, Bruno
    Latagliata, Roberto
    Spinsanti, Marco
    Kallenberg, Lydia
    Palumbo, Giuseppe Alberto
    Abruzzese, Elisabetta
    Scaffidi, Luigi
    Cuneo, Antonio
    Cavo, Michele
    Vianelli, Nicola
    Bonifacio, Massimiliano
    [J]. HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 285 - 290
12345